体外受精对多囊卵巢综合征不同表型的有效性

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Polycystic ovary syndrome occupies a leading place in the structure of endocrine infertility. This article presents the endocrine and metabolic features of the polycystic ovary syndrome phenotypes, as well as modern concepts of efficiency and complications of the use of assisted reproductive technologies, depending on the specific phenotype. The issues of polycystic ovary syndrome influence on selecting the method of assisted reproductive technologies, as well as possible complications that occur during in vitro fertilization and the features of the pregnancy course remain unresolved. The individualization of the approach seems to be promising when taking into account the differences in the hormonal profile and the features of metabolic disorders in each polycystic ovary syndrome phenotype. That may allow us to take one more step towards improving the effectiveness of in vitro fertilization and reducing the frequency of complications in patients with polycystic ovary syndrome.

作者简介

Igor Nikolayenkov

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: nikolaenkov_igor@mail.ru
ORCID iD: 0000-0003-2780-0887
SPIN 代码: 5571-4620

MD, Cand. Sci. (Med.), Head of the Educational-Methodical Department

俄罗斯联邦, 3 Mendeleevskaya Line, Saint Petersburg, 199034

Olga Kazymova

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott

Email: olia.merk@yandex.ru
ORCID iD: 0000-0003-3869-010X
SPIN 代码: 5986-3469

clinical resident

俄罗斯联邦, 3 Mendeleevskaya Line, Saint Petersburg, 199034

Dmitry Sudakov

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott; North-Western State Medical University named after I.I. Mechnikov

Email: suddakovv@yandex.ru
ORCID iD: 0000-0002-5270-0397
SPIN 代码: 6189-8705

MD, Cand. Sci. (Med.), Assistant Professor of the Department of Obstetrics and Gynecology, Cheef of the Simulation Centre

俄罗斯联邦, 3 Mendeleevskaya Line, Saint Petersburg, 199034; 41 Kirochnaya Str., Saint Petersburg, 191015

Yulia Dymarskaya

North-Western State Medical University named after I.I. Mechnikov

编辑信件的主要联系方式.
Email: julia_dym@mail.ru
ORCID iD: 0000-0001-6027-6875
SPIN 代码: 4195-3410

MD, Cand. Sci. (Med.), Assistant, The Department of Obstetrics and Gynecology

俄罗斯联邦, 41 Kirochnaya Str., Saint Petersburg, 191015

参考

  1. Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132(2):321–336. doi: 10.1097/AOG.0000000000002698
  2. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. doi: 10.1038/nrdp.2016.57
  3. Abashova EI, Shalina MA, Misharina EV, et al. Clinical features of polycystic ovary syndrome phenotypes in women with normogonadotropic anovulation in reproductive age. Journal of Obstetrics and Women’s Diseases. 2019;68(3):7–14. (In Russ.). doi: 10.17816/JOWD6837-14
  4. Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic Ovary Syndrome. Am Fam Physician. 2016;94(2):106–113.
  5. Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15. doi: 10.1016/j.fertnstert.2016.05.003
  6. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855. doi: 10.1093/humrep/dew218
  7. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454–1460. doi: 10.1016/j.fertnstert.2004.11.070
  8. Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001;16(9):1995–1998. doi: 10.1093/humrep/16.9.1995
  9. Krentz AJ, von Mühlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause. 2007;14(2):284–292. doi: 10.1097/GME.0b013e31802cc7ab
  10. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111(8):607–613. doi: 10.1016/s0002-9343(01)00948-2
  11. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000;52(5):595–600. doi: 10.1046/j.1365-2265.2000.01000.x
  12. Jedel E, Waern M, Gustafson D, et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod. 2010;25(2):450–456. doi: 10.1093/humrep/dep384
  13. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347–363. doi: 10.1093/humupd/dmq001
  14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. doi: 10.1016/j.fertnstert.2003.10.004
  15. Chernukha GE, Blinova IV, Kuprashvili MI. Endocrine and metabolic characteristics of patients with different phenotypes of polycystic ovary syndrome. Obstetrics and Gynecology. 2011;(2):70–76. (In Russ.)
  16. Mortada R, Williams T. Metabolic Syndrome: Polycystic Ovary Syndrome. FP Essent. 2015;435:30–42.
  17. Ehrmann DA, Liljenquist DR, Kasza K, et al.; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):48–53. doi: 10.1210/jc.2005-1329
  18. Brower M, Brennan K, Pall M, Azziz R. The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. J Clin Endocrinol Metab. 2013;98(12):E1967–71. doi: 10.1210/jc.2013-2815
  19. Kim JJ, Hwang KR, Choi YM, et al. Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome. Fertil Steril. 2014;101(5):1424–1430. doi: 10.1016/j.fertnstert.2014.01.049
  20. Welt CK, Gudmundsson JA, Arason G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. 2006;91(12):4842–4848. doi: 10.1210/jc.2006-1327
  21. Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf). 2007;67(5):735–742. doi: 10.1111/j.1365-2265.2007.02954.x
  22. Carmina E, Chu MC, Longo RA, et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90(5):2545–2549. doi: 10.1210/jc.2004-2279
  23. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15(4):477–488. doi: 10.1093/humupd/dmp008
  24. Misharina EV, Borodina VL, Glavnova OB, et al. Insulin resistance and hyperinsulinemia. Journal of Obstetrics and Women’s Diseases. 2016;65(1):75–86. (In Russ.). doi: 10.17816/JOWD65175-86
  25. Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci. 2011;16(6):763–769.
  26. Goverde AJ, van Koert AJ, Eijkemans MJ, et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod. 2009;24(3):710–717. doi: 10.1093/humrep/den433
  27. Di Fede G, Mansueto P, Longo RA, et al. Influence of sociocultural factors on the ovulatory status of polycystic ovary syndrome. Fertil Steril. 2009;91(5):1853–1856. doi: 10.1016/j.fertnstert.2008.02.161
  28. Melo AS, Vieira CS, Romano LG, et al. The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism. Reprod Sci. 2011;18(12):1230–1236. doi: 10.1177/1933719111414205
  29. Wijeyaratne CN, Seneviratne Rde A, Dahanayake S, et al. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum Reprod. 2011;26(1):202–213. doi: 10.1093/humrep/deq310
  30. Jones H, Sprung VS, Pugh CJ, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97(10):3709–3716. doi: 10.1210/jc.2012-1382
  31. Salim R, Serhal P. IVF in Polycystic ovary syndrome. In: Diagnosis and Management of Polycystic Ovary Syndrome. Farid NR, Diamantis-Kandarakis E, editors. Boston: Springer US; 2009. P. 253–258. [cited 2021 May 12]. Available from: https://link.springer.com/content/pdf/10.1007 %2F978-0-387-09718-3.pdf. doi: 10.1007/978-0-387-09718-3_21
  32. Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2016;293(2):447–456. doi: 10.1007/s00404-015-3889-5
  33. Nikolaenkov IP. Antimyllerov gormon v patogeneze sindroma polikistoznykh yaichnikov. [dissertation abstract] Saint Petersburg; 2014. (In Russ.). [cited 2021 May 12]. Available from: https://www.dissercat.com/content/antimyullerov-gormon-v-patogeneze-sindroma-polikistoznykh-yaichnikov. doi: 10.1007/978-0-387-09718-3_21
  34. Zhang HY, Zhu FF, Xiong J, et al. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG. 2009;116(12):1633–1639. doi: 10.1111/j.1471-0528.2009.02347.x
  35. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril. 2010;94(6):2197–2201. doi: 10.1016/j.fertnstert.2010.02.014
  36. Panidis D, Tziomalos K, Papadakis E, et al. Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. Hormones (Athens). 2015;14(3):431–437. doi: 10.14310/horm.2002.1593
  37. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038–2049. doi: 10.1210/jc.2009-2724
  38. Sha T, Wang X, Cheng W, Yan Y. A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. Reprod Biomed Online. 2019;39(2):281–293. doi: 10.1016/j.rbmo.2019.03.203
  39. March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–551. doi: 10.1093/humrep/dep399
  40. Nikolayenkov IP, Kuzminykh TU, Tarasova MA, Seryogina DS. Features of the course of pregnancy in women with polycystic ovary syndrome. Journal of Obstetrics and Women’s Diseases. 2020;69(5):105–112. doi: 10.17816/JOWD695105-112
  41. Wei D, Shi Y, Li J, Wang Z, et al. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome. Hum Reprod. 2017;32(2):354–361. doi: 10.1093/humrep/dew325
  42. Cela V, Obino MER, Alberga Y, et al. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes. Gynecol Endocrinol. 2018;34(6):518–523. doi: 10.1080/09513590.2017.1412429
  43. Celkovich LS, Ivanova TV, Ibragimova AR, et al. Sravnitel’naya ocenka protokolov EKO u zhenshchin s razlichnymi klinicheskimi variantami techeniya sindroma polikistoznyh yaichnikov. Aspirantskij vestnik Povolzh’ya. 2017;17(5–6):97–103. (In Russ.)
  44. Bezirganoglu N, Seckin KD, Baser E, et al. Isolated polycystic morphology: Does it affect the IVF treatment outcomes? J Obstet Gynaecol. 2015;35(3):272–274. doi: 10.3109/01443615.2014.948407
  45. De Vos M, Pareyn S, Drakopoulos P, et al. Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters. Reprod Biomed Online. 2018;37(2):163–171. doi: 10.1016/j.rbmo.2018.05.003
  46. Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol. 2011;204(6):558.e1–6. doi: 10.1016/j.ajog.2011.03.021
  47. Wan HL, Hui PW, Li HW, Ng EH. Obstetric outcomes in women with polycystic ovary syndrome and isolated polycystic ovaries undergoing in vitro fertilization: a retrospective cohort analysis. J Matern Fetal Neonatal Med. 2015;28(4):475–478. doi: 10.3109/14767058.2014.921673
  48. Thakre N, Homburg R. A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome. Expert Rev Endocrinol Metab. 2019;14(5):315–319. doi: 10.1080/17446651.2019.1631797
  49. Lee TH, Liu CH, Huang CC, et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod. 2008;23(1):160–167. doi: 10.1093/humrep/dem254
  50. Lin K, Coutifaris C. In vitro fertilization in the polycystic ovary syndrome patient: an update. Clin Obstet Gynecol. 2007;50(1):268–276. doi: 10.1097/GRF.0b013e3180305fe4
  51. Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;2014(11):CD006105. Corrected and republished from: Cochrane Database Syst Rev. 2020;12:CD006105. doi: 10.1002/14651858.CD006105.pub3
  52. Gleicher N, Kushnir VA, Darmon SK, et al. New PCOS-like phenotype in older infertile women of likely autoimmune adrenal etiology with high AMH but low androgens. J Steroid Biochem Mol Biol. 2017;167:144–152. doi: 10.1016/j.jsbmb.2016.12.004
  53. Bozdag G, Mumusoglu S, Coskun ZY, et al. Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population. Reprod Biomed Online. 2019;39(3):522–529. doi: 10.1016/j.rbmo.2019.04.002.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Nikolayenkov I., Kazymova O., Sudakov D., Dymarskaya Y., 2021



##common.cookie##